Neural Analytics wins CE Mark for next-gen Lucid transcranial ultrasound

Neural Analytics said today it won CE Mark approval in the European Union for its next-gen Lucid M1 transcranial doppler ultrasound system.

The Los Angeles-based company’s Lucid M1 is a portable all-in-one ultrasound system designed for rapid triaging and monitoring of patients with brain disorders.

“The development of accurate and portable brain monitoring technology like the Lucid System is critical to expanding brain care in the 21st century. Healthcare professionals will be able to utilize this diagnostic tool in a variety of clinical settings to accurately measure the brain’s blood flow to expedite medical care across a range of neurological disorders,” Dr. Kyriakos Lobotesis of the U.K.’s Imperial College Healthcare NHS Trust said in prepared remarks.

Neural Analytic’s system is a battery operated medical grade tablet device which uses transcranial doppler to assess the brains blood vessels from outside the body. Analyses with the system can be performed in office and can help diagnose brain disorders and avoid more invasive tests, the company said.

“The CE Mark for our Lucid System represents an important milestone for Neural Analytics as it will allow us to bring a non-invasive device to patients with blood flow disorders in Europe who may benefit from this portable monitoring system,” CEO Leo Petrossian said in a press release.

Neural Analytics said it is hopeful for a commercial launch of the device in Europe immediately.

Last September, Neural Analytics said it landed a $3 million grant from the National Institutes of Health for the diagnostic and monitoring technology it’s developing for traumatic brain injury and stroke. The NIH’s Small Business Innovation Research program funded the grant.

The post Neural Analytics wins CE Mark for next-gen Lucid transcranial ultrasound appeared first on MassDevice.

from MassDevice http://ift.tt/2kktwjk